 |
PDBsum entry 3ilu
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Membrane protein
|
PDB id
|
|
|
|
3ilu
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Probing the allosteric modulator binding site of glur2 with thiazide derivatives.
|
 |
|
Authors
|
 |
C.P.Ptak,
A.H.Ahmed,
R.E.Oswald.
|
 |
|
Ref.
|
 |
Biochemistry, 2009,
48,
8594-8602.
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Ionotropic glutamate receptors mediate the majority of vertebrate excitatory
synaptic transmission and are therapeutic targets for cognitive enhancement and
treatment of schizophrenia. The binding domains of these tetrameric receptors
consist of two dimers, and the dissociation of the dimer interface of the
ligand-binding domain leads to desensitization in the continued presence of
agonist. Positive allosteric modulators act by strengthening the dimer interface
and reducing the level of desensitization, thereby increasing steady-state
activation. Removing the desensitized state for simplified analysis of receptor
activation is commonly achieved using cyclothiazide (CTZ), the most potent
modulator of the benzothiadiazide class, with the flip form of the AMPA receptor
subtype. IDRA-21, the first benzothiadiazide to have an effect in behavioral
tests, is an important lead compound in clinical trials for cognitive
enhancement as it can cross the blood-brain barrier. Intermediate structures
between CTZ and IDRA-21 show reduced potency, suggesting that these two
compounds have different contact points associated with binding. To understand
how benzothiadiazides bind to the pocket bridging the dimer interface, we
generated a series of crystal structures of the GluR2 ligand-binding domain
complexed with benzothiadiazide derivatives (IDRA-21, hydroflumethiazide,
hydrochlorothiazide, chlorothiazide, trichlormethiazide, and althiazide) for
comparison with an existing structure for cyclothiazide. The structures detail
how changes in the substituents at the 3- and 7-positions of the
hydrobenzothiadiazide ring shift the orientation of the drug in the binding site
and, in some cases, change the stoichiometry of binding. All derivatives
maintain a hydrogen bond with the Ser754 hydroxyl, affirming the partial
selectivity of the benzothiadiazides for the flip form of AMPA receptors.
|
 |
|
|
|
|
 |